|Bid||165.33 x 100|
|Ask||180.00 x 100|
|Day's Range||168.28 - 173.35|
|52 Week Range||34.36 - 182.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BeiGene (BGNE) stock has risen 16.9%, from $143.73 on March 1, 2018, to $168 on March 29, 2018. Originally founded as a research and development company, BeiGene has evolved into a biopharmaceutical company focused on developing oncology therapies such as BTK inhibitor zanubrutinib, PD-1 antibody tislelizumab, and PARP inhibitor pamiparib.
LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (LSE:HCM.L - News), Beigene (NasdaqGS:BGNE - News) and Zai Lab (NasdaqGM:ZLAB - News) have soared on international markets this year, fueled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (LSE:AZN.L - News).